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ABSTRACT Potent systemic immunity is important for recalled mucosal immune
responses, but in the defense against mucosal viral infections, it usually remains low
at mucosal sites. Based on our previous findings that enhanced immune responses
can be achieved by immunization with an immunogen in combination with a molec-
ular adjuvant, here we designed chemokine-antigen (Ag) fusion constructs (CCL19-
or CCL28-herpes simplex virus 2 glycoprotein D [HSV-2 gD]). After intramuscular
(i.m.) immunization with different DNA vaccines in a prime and boost strategy,
BALB/c mice were challenged with a lethal dose of HSV-2 through the genital tract.
Ag-specific immune responses and chemokine receptor-specific lymphocytes were
analyzed to determine the effects of CCL19 and CCL28 in strengthening humoral
and cellular immunity. Both CCL19 and CCL28 were efficient in inducing long-lasting
HSV-2 gD-specific systemic immunity. Compared to CCL19, less CCL28 was required
to elicit HSV-2 gD-specific serum IgA responses, Th1- and Th2-like responses of im-
munoglobulin (Ig) subclasses and cytokines, and CCR31 T cell enrichment (.8.5-fold)
in spleens. These findings together demonstrate that CCL28 tends to assist an immu-
nogen to induce more potently protective immunity than CCL19. This work provides
information for the application potential of a promising vaccination strategy against
mucosal infections caused by HSV-2 and other sexually transmitted viruses.
IMPORTANCE An effective HSV-2 vaccine should induce antigen (Ag)-specific immune
responses against viral mucosal infection. This study reveals that chemokine CCL19 or
CCL28 enhanced HSV-2 glycoprotein D ectodomain (gD-306aa)-induced immune
responses against vaginal virus challenge. In addition to eliciting robust humoral
immune responses, the chemokine-Ag fusion construct also induced Th1- and Th2-like
immune responses characterized by the secretion of multiple Ig subclasses and cyto-
kines that were able to be recalled after HSV-2 challenge, while CCL28 appeared to be
more effective than CCL19 in promoting gD-elicited immune responses as well as the
migration of T cells to secondary lymph tissues. Of importance, both CCL19 and CCL28
significantly facilitated gD to induce protective mucosal immune responses in the geni-
tal tract. The above-described findings together highlight the potential of CCL19 or
CCL28 in combination with gD as a vaccination strategy to control HSV-2 infection.
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Genital herpes is a sexually transmitted disease. Although herpes simplex virus 1(HSV-1) can cause genital herpes, most cases of genital herpes are caused by HSV-2,
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which infects the host mainly through the mucosa of the genital tract (1). More than 400
million individuals are infected by HSV-2 worldwide, resulting in significant global finan-
cial burden (1). HSV-2 replicates predominantly in the mucosal epithelial cells and estab-
lishes latency in the innervating neurons. HSV-2 infection can also increase the risk of HIV-
1 transmission (2–4). Although protective vaccines against HSV-2 are persistently pursued
and considerable efforts and expenditures have been made over the past several deca-
des, such a vaccine remains elusive (5). For instance, an HSV-2 gD subunit vaccine com-
bined with adjuvants consisting of 3-O-deacylated monophosphoryl lipid A and alum
(MPL-alum) has not conferred significant efficacy against HSV-2 infection in the popula-
tion (6). The genital tract and the rectal mucosae are portals of entry for sexually transmit-
ted infections (STIs); however, they are immunologically restrictive tissues that prevent
entry of activated and systemic memory T cells (7). Therefore, developing a vaccine
against HSV-2 at the mucosal portals of entry could be the ideal strategy to control and
prevent the disease.
CCL19 and CCL28, as molecular adjuvants, were recently described as potent ele-
ments for promoting cellular immune responses in systemic circulation and the muco-
sae, based on their potential impacts on T- and B-cell activation (8–11). CCL19 is one of
the key molecules involved in establishing functional microenvironments for the initia-
tion of immune responses in secondary lymphoid tissues (12, 13). CCL19, through
interactions with its cognate receptor CCR7, plays a pivotal role in recruiting responsive
immunocytes, including antigen (Ag)-specific or nonspecific T cells, B cells, and
matured dendritic cells (DCs) (13, 14), to secondary lymphoid organs. CCL19 as a mo-
lecular adjuvant has been proven to be useful in several immunization models and is
capable of promoting Ag-specific humoral and cellular immune responses in combina-
tion with vaccine candidates, including HSV-1 gB (15), HIV-1 Env (8), pseudorabies virus
gB (16), and hepatitis C virus (HCV) core DNA (17). CCL28 is widely expressed in mouse,
human, and pig mucosal tissues, including the mammary gland, salivary gland, small
and large intestines, and trachea, where it appears to be predominantly produced by
epithelial cells (18). CCL28 can bind to CCR3 and CCR10 receptors and plays essential
roles in both innate and adaptive immunity, primarily by recruiting leukocytes to sec-
ondary lymphoid tissues and by extravasation of IgA antibody (Ab)-secreting cells (IgA
ASCs) to mucosal surfaces in the gut and lactating mammary gland (18). The role of
chemokines as adjuvants in inducing mucosal immune responses has been extensively
assessed in HIV-1 (8, 11, 19, 20) and influenza A (21–24). In addition, these mucosal im-
munity-associated chemokines have been evaluated in helping lymphocytes to release
antiviral-related cytokines, such as gamma interferon (IFN-g) and interleukin-4 (IL-4),
which can further promote T cell proliferation and Ag uptake by DCs (8, 25). However,
the mechanisms of and differences between CCL19 and CCL28 as adjuvants in promot-
ing HSV-2 glycoprotein D (gD)-specific mucosal immunity, especially protecting ani-
mals from intravaginal (i.vag.) virus challenge, need further exploration, which may
facilitate the development of more potent, durable, and safe T cell-based antiviral
pharmaceuticals or vaccines.
Using mice as a vaccination and challenge model, we searched for approaches to
improve HSV-2 glycoprotein immunogenicity. For comparison purposes, we first pro-
duced bicistronic- and chimeric-expressing DNA vectors using an internal ribosome
entry site (IRES)- and a GCN4-based isoleucine zipper trimerization domain (IZ) linker,
respectively. The GCN4-based linker allowed us to develop stabilized native-like multi-
mers and facilitated the coexpression of Ags and chemokines (26, 27). We further com-
pared the capability of CCL19 and CCL28 in assisting an immunogen to induce protec-
tive immune responses against HSV-2 infection.
RESULTS
Construction and characterization of bicistronic- and IZ-based chemokine-Ag
DNA vectors. Bicistronic- or IZ-based chemokine-Ag DNA plasmids were designed to
ensure the coexpression of HSV-2 gD with chemokine CCL19 or CCL28 within the same
cell (Fig. 1A; see also Tables S1 and S2 and Fig. S1A in the supplemental material). The
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FIG 1 Construct design, immunization procedures, and humoral immune responses of sera and vaginal lavage fluid. (A) Schematics of chemokine-
linker-gD and gD-linker-chemokine constructs. (B) Schedule of i.m. immunization and i.vag. challenge. Mice (n= 10) were immunized twice with
(Continued on next page)
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effects of IRES- and IZ-based DNA vaccines were compared with Ag DNA and corre-
sponding chemokine DNA in combination in vivo. We first compared the immunoge-
nicity of constructs with CCL19 or CCL28 on the upstream or downstream of HSV-2 gD.
Following immunization and animal protection study, we found that pgD-IRES/IZ-
CCL19 and pCCL28-IRES/IZ-gD induced better immune responses (Table S3, Fig. S1B).
Among all the tested fusion constructs, pCCL28-IZ-gD induced the best protection im-
munity in mice, with a symptom score of zero after HSV-2 challenge. Therefore, we
selected this construct for the downstream study. As evidenced by Western blotting,
the gD portion of the pCCL28-IZ-gD fusion protein construct was successfully
expressed in the cell line to a level similar to that of the gD protein as a dimer
(Fig. S1C). Further Western blot and enzyme-linked immunosorbent assay (ELISA) anal-
yses showed that the proteins of gD, CCL19, and CCL28 in the supernatants of trans-
fected HEK 293T cells (in vitro) and immunized mice (in vivo) were correctly expressed
(Fig. S1B and S1D). Notably, due to the different standard products in the CCL19 and
CCL28 ELISA kits, the chemokines displayed distinct expression (Fig. S1D).
CCL19 and CCL28 are potent in assisting HSV-2 gD to induce long-lasting
humoral responses postimmunization.We have previously found that CCL19 enhan-
ces the immunogenicity of HSV-2 gB (28), but little is known about the role and the
mechanism of CCL28 in promoting antiviral responses during reproductive tract infec-
tion. After immunization of all plasmid groups in BALB/c mice (Fig. 1A and B, Table S3),
we compared the gD-specific IgG in murine sera at 2 weeks postboost of all groups
(Fig. S1B) and the acute disease severities after HSV-2 challenge (Table S3). The results
showed that only pgD plus pCCL19 (10mol and 20mol), pgD plus pCCL28 (1mol,
10mol, and 20mol), and pCCL28-IZ-gD (1mol) groups scored zero for symptom sever-
ity during the observational days postinfection (dpi) (Table S3). As shown in Fig. 1C,
mice coimmunized with 1mol pgD plus 20mol pCCL19 or 10mol pCCL28, or 1mol
pCCL28-IZ-gD fusion construct, significantly enhanced the levels of gD-specific IgG and
IgA titers, compared to the pgD plus pcDNA3.1 group in both sera and vaginal lavage
fluid at 2 weeks postboost. Notably, we observed that mice coimmunized with more
CCL28 (20mol) had ruffled hair and low level of serum IgA but a high level of mucosal
IgA, indicating that 20mol pCCL28 injection caused some side effects and difference of
IgA expression in blood and mucosae. Altogether, the amount of CCL28 required may
be less than that required for CCL19 to induce a similar level of effective humoral im-
munity. Additionally, the chimeric construct pCCL28-IZ-gD showed a distinct ability to
enhance gD-specific systemic and mucosal Ab responses.
The duration and quality of humoral immunity and the generation of immunologi-
cal memory are critical for generating protective immunity. To investigate whether gD
coimmunized with mucosa-associated chemokines could induce potent and long-last-
ing humoral immunity postimmunization and postchallenge, mice were coimmunized
with gD and chemokines and then challenged with lethal HSV-2 at 9 weeks postboost.
Murine sera were collected for gD-specific IgG and IgA titrations postboost and post-
challenge for several weeks as indicated in Fig. 1B. As shown in Fig. 1D, all chemokine
coimmunized mice displayed enhanced titers of gD-specific IgG until 9 weeks post-
boost compared with the responses of the pgD plus pcDNA3.1 group. Compared with
the pgD plus 1mol pCCL28 group, mice immunized with pCCL28-IZ-gD developed a
similar magnitude of antibody (Ab) response. For the detection of serum gD-specific
FIG 1 Legend (Continued)
pcDNA3.1, pgD 1 pcDNA3.1, pgD 1 pCCL19, or pCCL28 chemokine-Ag plasmids in saline solution at 0 and 2 weeks. Two weeks postboost, mice
(n= 5) in each group were sacrificed for tissue collection, while the rest were used for the challenge experiments. Postchallenge, the weight and
clinical symptoms of all mice were monitored every day for 15 days. Murine sera, vaginal lavage, and sacral ganglia were collected at the indicated
time points for subsequent tests. (C) Humoral immune responses induced by pgD in combination with pCCL19 or pCCL28 and pCCL28-IZ-gD. Mice
were immunized i.m. at 0 and 2 weeks by electroporation. At 2 weeks (wk) postboost, sera and vaginal lavage fluid were collected and an endpoint
titration of gD-specific IgG and IgA was measured by ELISA. Data are the means 6 SEM, n= 10 mice per group, from at least two independent
experiments with each condition being performed in duplicate. (D) Serum gD-specific IgG was compared for each group at the indicated weeks
postboost. (E) Serum gD-specific IgA at 7 weeks postboost was compared for each group. Data shown are the means 6 SEM (n= 5 mice/group) from
three independent experiments with each condition performed in duplicate. Statistically significant differences were determined by comparison to the
pgD 1 pcDNA3.1 group. NS, not statistically significant; *, P, 0.05; **, P , 0.01; ***, P, 0.001; ****, P, 0.0001.
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IgA at 7 weeks postboost, gD coimmunized with CCL28 (1mol or 10mol pCCL28 or the
pCCL28-IZ-gD chimeric construct) showed relatively higher mucosal Ab titers (IgA)
than pgD plus 20mol pCCL19 (almost 2-fold increased; Fig. 1E). Here, CCL28 is more
effective than CCL19 in promoting long-lasting mucosal immunity postimmunization.
CCL19 and CCL28 are potent in assisting HSV-2 gD to induce a robust humoral
response and overall magnitude of gD-specific Ig subclasses in serum
postchallenge. Post-HSV-2 challenge, there was a nearly 2-fold increase in the recall of
serum gD-specific IgG in most of the chemokine-coimmunized groups compared with
pgD plus pcDNA3.1 (Fig. 2A). Of note, the pgD plus pcDNA3.1 group had an initial
increase in humoral gD-specific IgG and IgA titer at 5 dpi, and the highest level of
responding Ab in the chemokine coimmunized groups appeared at 9 dpi and remained
up to 30dpi, whereas antibody titers of the experimental groups with good protection
effects decreased gradually (Fig. 2A and B). In particular, the pCCL28-IZ-gD group devel-
oped higher levels of gD-specific IgG and IgA compared to pgD plus pCCL28 (1mol) at
7dpi and 9dpi, respectively. In general, coimmunization with gD and CCL28 plasmid
showed a comparable ability to enhance the duration of Ag-specific IgG and IgA in sera
postboost and postchallenge. In contrast, the Ab titer results suggested that the chimeric
construct was more stable and effective than a 1:1 mixture of pgD with pCCL28; the other
deserted vaccinated groups did not all produce such high levels of recalled Ab titers
(data not shown). Therefore, in the following studies we used 1mol pgD mixed with
20mol pCCL19 or 10mol pCCL28 and 1mol pCCL28-IZ-gD.
It has been previously described that mice immunized with a plasmid encoding
HSV-2 gD had a substantial level of specific IgG in their sera, which was almost exclu-
sively of the IgG1 isotype and not IgG2a or IgG2b (29, 30). To test whether the pCCL19
or pCCL28 chemokine simply mixed with pgD was functional in modulating the iso-
types of the antibody responses, we examined the levels of gD-specific IgG subtypes
(IgG1, IgG2a, IgG2b, and IgG3) and IgM by ELISA in sera collected at 2 weeks postboost
and 9 days postchallenge. The IgG2a/IgG1 ratio was used as a surrogate marker of Th1
and Th2 responses (27). Here, we measured the gD-specific IgG2a/IgG1 ratio to evalu-
ate the type of Th response induced by our vaccine formulations. Among the four IgG
subtypes in mice, only IgG1 is associated with a Th2 profile (31). Among the four DNA
vaccines, mice immunized with pgD plus 10mol pCCL28 developed significantly aug-
mented Th1 and Th2 responses (IgG1, IgG2a, IgG3, and IgM) compared with pgD plus
pcDNA3.1 at 2 weeks postboost, whereas other groups only enhanced Th1 subclass
responses (IgG2a, IgG3, and IgM) (Fig. 2C, upper). However, all groups switched to
enhance all Ig subclass responses after HSV-2 i.vag. challenge (9 dpi), and the magni-
tude of the gD-specific IgG2a subclass was significantly augmented in the pgD plus
pCCL28 group (Fig. 2C, lower). As shown in Fig. 2D, the CCL19 (20mol) and CCL28
(1mol and 10mol) chemokines all helped to augment Th1-biased Ig subclass
responses compared with pgD plus pcDNA3.1; notably, pgD coimmunized with 10mol
pCCL28 showed a dramatic increase (nearly 5-fold) in the Th1-biased response com-
pared with pgD plus pcDNA3.1 at 9 dpi. Taken together, these results suggest that pgD
coimmunized with higher doses of pCCL28 (10mol) significantly augmented the Th1-
biased gD-specific Ig subclasses in recalled responses compared with pgD plus pCCL19
and pgD plus pcDNA3.1, while CCL28 and gD used in a chimeric construct is capable
of augmenting gD-specific antibody responses toward a balanced Th1 and Th2 profile
in protective immune responses.
CCL19 and CCL28 are potent in assisting HSV-2 gD to induce neutralizing
responses in sera and vaginal lavage fluids. The results described above demon-
strated that pgD coimmunized with pCCL19 or pCCL28 plasmids or a pCCL28-IZ-gD
chimeric construct can significantly augment the magnitudes of systemic and mucosal
Ab responses and their subclasses to gD. There is well-documented evidence in animal
models that an efficacious prophylactic HSV-2 vaccine will most likely induce a robust
neutralizing antibody response, especially at mucosal sites (2, 32, 33). We next assessed
whether such increases in antibodies correlated with concomitant increases in viral
neutralizing responses, especially post-HSV-2 challenge. The neutralizing activities of
CCL19 and CCL28 Enhance Systemic Immunity
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sera collected at 2 weeks and 7 weeks postboost and at 5, 9, and 11 dpi, and vaginal la-
vage fluid at 2 weeks postboost were tested. As shown in Fig. 3, neutralizing activities
of sera and vaginal lavage fluid against HSV-2 were significantly enhanced at the indi-
cated time points in mice immunized with pgD plus pCCL19 or CCL28 or the pCCL28-
IZ-gD chimeric construct compared to the pgD plus pcDNA3.1 group. Notably, the
neutralizing activity of sera remained apparent in the pgD plus pCCL19 group up to 7
weeks postboost and appeared to remain at a higher level than the CCL28 group
before 9 dpi, but the neutralizing antibody in the mucosae showed no advantage. In
addition, the neutralizing activity peaked at 9 dpi and remained constant in the CCL28
group up to 11 dpi. Taken together, the neutralizing activity of sera from mice immu-
nized with pgD plus pcDNA3.1 was significantly lower than that of mice coimmunized
with gD and chemokines. Our results suggest that both CCL19 and CCL28 tend to
assist an immunogen to induce more sustainable and potent neutralizing antibody
responses than the pgD plus pcDNA3.1 group postchallenge.
CCL19 and CCL28 are potent in assisting HSV-2 gD to promote Ag-specific Th1
and Th2 cellular immune responses. It has been suggested that CCL19 and CCL28, as
key regulators in vivo, regulate T cell and DC-dependent adaptive immune responses,
resulting in lymphoproliferative responses and indirectly inducing B cell upregulation
FIG 2 gD-specific IgG and IgA responses and Ig subclasses in serum postchallenge. Serum gD-specific IgG (A) and IgA (B) at indicated days postboost and
postchallenge. The endpoint titrations of gD-specific IgG and IgA were determined by ELISA separately. (C) The distribution of gD-specific IgG1, IgG2a,
IgG2b, IgG3, and IgM isotypes in murine sera at 2 weeks postboost (upper) and 9 dpi (lower). (D) gD-specific IgG2a/IgG1 ratio of the different groups at 2
weeks postboost and 9 dpi. The quantification of each Ig subclass was measured by ELISA and calculated according to the standard curve obtained using
corresponding Ig subclass standards. CCL19, 20mol; CCL28, 10mol. Data are the means 6 SEM, n= 5 or 7 mice per group, from at least two independent
experiments with each condition being performed in duplicate. Statistically significant differences determined by comparison to the pgD 1 pcDNA3.1
group are indicated. NS, not statistically significant; *, P, 0.05; **, P , 0.01; ***, P, 0.001.
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(8, 17). We used the same concept to speculate that codelivery of pgD with the
pCCL19 or pCCL28 plasmid can target and activate Ag-specific immunocytes and pro-
duce balanced Th1- and Th2-like cellular immune responses to substantially improve
the protective effects of the DNA vaccine. It is generally known that IL-2, tumor necro-
sis factor alpha (TNF-a), and IFN-g are associated with a Th1 profile, whereas IL-4 and
IL-5 are associated with a Th2 profile. Given the central roles of cytokines secreted by
activated immunocytes in defining the subsequent immune responses, we next eval-
uated Ag-specific Th1- or Th2-like cellular immune responses by measuring the associ-
ated cytokines secreted by murine splenocytes postboost and postchallenge in
response to gD protein stimulation. As shown in Fig. 4A, splenocytes of mice coimmu-
nized with pgD (1mol) and pCCL19 (20mol) or pCCL28 (10mol) or the pCCL28-IZ-gD
(1mol) chimeric construct produced enhanced levels of Th1- and Th2-associated cyto-
kines compared with pgD plus pcDNA3.1 after HSV-2 gD stimulation in vitro postboost.
However, compared with the pgD plus pcDNA3.1 group, the pgD plus pCCL19 group
induced relatively higher levels of cytokines at 5 dpi, although it was lower than that in
mice coimmunized with pgD plus pCCL28 or pCCL28-IZ-gD. Interestingly, the pgD plus
pCCL28 group developed higher levels of overall Ag-specific Th1- and Th2-like cyto-
kines post-HSV-2 challenge, while the pCCL28-IZ-gD chimeric construct developed
higher levels of IL-2, IL-5, and IFN-g at 9 dpi than the pgD plus pCCL19 group (Fig. 4B
and C). In contrast, supernatants from the negative-control group (pcDNA3.1) demon-
strated that IL-2, IL-4, and IL-5 levels were below the limits of detection postboost,
while there were significantly higher levels of inflammation-related cytokines IFN-g and
TNF-a at 5 dpi and 9 dpi in antisera compared with the pgD plus pcDNA3.1 group, con-
sistent with their disease severity (Fig. 4A); we speculated that this was associated with
the expression of viral immune evasion genes and the inflammatory response to virus-
infected cells (severe and critical inflammation was observed in mice). Collectively,
these results indicate that codelivery of CCL28 DNA vaccines is capable of strengthen-
ing the magnitude and duration (up to 9 dpi) of Th1- and Th2-like Ag-specific cellular
responses in protective immune responses.
CCL19 and CCL28 are potent in chemoattracting Ag-responding T cells to
secondary lymph nodes. Following the demonstration that codelivery of pgD (1mol)
and pCCL19 (20mol) or pCCL28 (10mol) or the pCCL28-IZ-gD (1mol) chimeric construct
could enhance gD-specific systemic and mucosal antibody responses as well as Th1- and
Th2-like cellular responses, we next investigated the underlying mechanisms of such an
immune enhancement. We previously demonstrated that CCL19 fused with HSV-2 gB
constructs could induce a responsive immunocyte increase in murine secondary lymph
nodes and at mucosal sites postimmunization (28). In contrast, CCL28 remains poorly
understood, especially with regard to its performance after virus challenge. It is widely
FIG 3 Anti-HSV-2-neutralizing activities of sera and vaginal lavage fluid from immunized mice. Murine sera
collected at the indicated times were tested at dilutions starting with 1:10 (at 2 weeks and 7 weeks postboost)
and 1:40 (at 5, 9, and 11dpi). Vaginal lavage fluid collected at 2 weeks postboost were tested at dilutions
starting with 1:5. Plaque numbers were determined for each sample and plotted as percent inhibition. NS, not
statistically significant; ***, P, 0.001.
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known that CCL19 and CCL28 are involved in trafficking the CCR71 and CCR3/CCR101
immunocytes, including IgA1 plasma cells, into colorectal mucosal sites, (8, 19, 20, 31),
but their promotional effects may be different during immune protection. According to
the role of IgA1 cells in the adaptive immune responses to pathogens at mucosal sites,
our immunohistochemistry results also showed that pgD coimmunized with pCCL19 or
pCCL28 or the pCCL28-IZ-gD chimeric construct developed increased IgA1 cells at a num-
ber of rectal sites (Fig. 5A); their cell numbers were increased up to nearly 1.8-fold com-
pared with the pgD plus pcDNA3.1 group (Fig. 5B). Notably, these results coincided with
gD-specific IgA titer changes in vaginal lavage fluid. In summary, codelivery of pCCL19 or
pCCL28 with pgD show comparable ability in attracting IgA1 cells to colorectal mucosal
sites, reflecting enhanced mucosal immune responses.
Similarly, spleen and mesenteric lymph nodes (MLNs) are important secondary
lymph nodes and mucosal sites, respectively, and they are associated with lymphocyte
homing and recycling in mice. As shown in Fig. 5C and D, these two chemokines effec-
tively induced the chemotaxis and migration of their responsive splenocytes and MLN
lymphocytes (MLNLs). Compared with pgD plus pcDNA3.1, mice coimmunized with
pgD plus pCCL19 or pCCL28 plasmids resulted in ;1.8- and 1.4-fold increases, respec-
tively, in the number of chemokine-responsive immunocytes that migrated to the
spleen, and ;2.6- and 2.4-fold increases, respectively, in the MLNs. In contrast, there
was a slight decrease in the MLNs with the pCCL28-IZ-gD group. In general, codelivery
FIG 4 Ag-specific Th1/Th2-associated cytokine production from splenocytes and antisera. (A) Cytokine production in splenocyte supernatants from
immunized mice (2 weeks postboost) and antisera after HSV-2 challenge (5 dpi and 9 dpi) was quantified by flow cytometry. (B) Fold changes in the pgD 1
pCCL28 or pCCL28-IZ-gD groups over the pgD 1 pCCL19 group. Splenocytes (1 107 cells) isolated from all groups postboost were stimulated with purified
gD (2mg/ml) and cocultivated for 5days, and then the supernatants were collected. (C) Hot map of cytokine fold changes (i.e., pgD 1 CCL28/pgD 1 CCL19
and pCCL28-IZ-gD/pgD 1 CCL19). Group 1, 1-1, and 1-2 is named pgD 1 CCL28/pgD 1 CCL19, and 2, 2-1, and 2-2 is named pCCL28-IZ-gD/pgD 1 CCL19.
Antisera were collected at 5 and 9dpi. The production of Th1 (IL-2, IFN-g, and TNF-a)- and Th2 (IL-4 and IL-5)-associated cytokines was detected using a CBA
kit. Data shown are representative of the mean cytokine concentrations (pg/ml) 6 SEM with n=5 mice per group. Statistically significant differences
determined by comparing to the pgD 1 pcDNA3.1 group are indicated. NS, not statistically significant; *, P, 0.05; ***, P, 0.001.
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of either pCCL19 or pCCL28 with pgD consistently resulted in higher levels of respon-
sive immunocyte influx into the spleen and MLNs, but the MLNL response was higher.
To better understand the performance of CCL19- or CCL28-mediated cellular im-
munity during challenge, we conducted assays to determine if the Ag-responding T
cells migrate to secondary lymph nodes after HSV-2 infection. CCR7 presents as a
defining factor for nonpolarized central (CCR71) and polarized effector memory
(CCR72) T cells (34). CCR7 is expressed at high levels on naive and central memory T
cells and enables homeostasis T cell subsets to recirculate and home to T cell areas
in lymphoid organs, such as the white pulp areas of the spleen and lymph nodes
(35, 36). We detected CCR71/2 or CCR31 T cells among splenocytes by flow cytome-
try postboost and postchallenge. As shown in Fig. 5E and 6F, CCR71/2 or CCR31 T
cell-sensitized lymphocytes increased significantly in spleens postchallenge. Mice
coimmunized with pgD plus pCCL19 showed an ;4-fold increase in CCR72 T cells
among splenocytes compared with the pgD plus pcDNA3.1 group postboost
FIG 5 Responsive immunocyte migration to secondary lymph nodes postimmunization and postchallenge. IgA1 cells at colorectal sites mediated by the
CCL19 or CCL28 adjuvant in immunized mice. (A) IgA1 cells in murine colorectal mucosal samples were stained with DBA and hematoxylin. Data shown are
representative immunohistochemistry results (magnification, 200). (B) Mean counts of IgA1 cells of 10 high-power fields for each group. Migration of
murine splenocytes and MLNLs for each group in response to murine CCL19 or CCL28 protein. Single lymphocytes were prepared and counted for the
chemotactic response to CCL19 or CCL28 using a Transwell system, and the fold changes were calculated compared to the cell number in the lower chamber
without CCL19 (C) or CCL28 (D). The frequencies of CCR71/2 (E) and CCR31 (F) CD31 splenocytes at 2 weeks postboost and 9dpi were analyzed by flow
cytometry. By comparing to the pgD 1 pcDNA3.1 group, the fold change of CCR72 (G) and CCR31 (H) CD31 splenocyte frequencies in the pCCL19 or pCCL28
adjuvant groups were calculated, and the gating strategies are shown in Fig. S1E. Data shown are the means 6 SEM for each group (n=5 mice/group).
Statistically significant differences determined by comparing to the pgD 1 pcDNA3.1 group are indicated. NS, not statistically significant; ***, P, 0.001.
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(Fig. 5G), but a significant increase of CCR71 T cell was found in the pgD plus
pCCL19 group postchallenge (;1.7-fold at 9 dpi) (Fig. 5E), while coimmunization
with pgD plus pCCL28 plasmids or the pCCL28-IZ-gD construct displayed up to
;10.2-fold and ;8.5-fold increases in CCR31 T cells in spleens postboost and post-
challenge (Fig. 5F and H), respectively. The advantage over CCL19 was that CCL28
developed consistent enhancement of CCR101 on B cells (CD191) and DC (CD11c1)
in immunized and challenged mice (Fig. S1E). Similar responses were found in the
MLNs (data not shown). Accordingly, these results suggested that codelivery of
CCL28 is more effective than CCL19 in enhancing cellular responses during protec-
tive immune responses.
CCL19 and CCL28 are potent in assisting HSV-2 gD to induce immune
protection against viral challenge in genital tract. The mouse models of HSV-2
infection have provided important insights into the immunobiology of genital her-
pes. Studies that measure the frequency and quantity of viral shedding detected
from the genital tract have provided insights into the natural history and pathoge-
nesis of HSV-2 infection. An alternative vaccination goal is to alter the natural history
of this infection by decreasing the quantity of virus that establishes latency in neu-
rons and minimizing the quantity of virus shed from genital surfaces (33). Several
candidate vaccines appear to reduce the quantity of HSV-2 in mouse and guinea pig
sacral nerves (2). We next tested whether the mice coimmunized with pgD (1mol)
and pCCL19 (20mol) or pCCL28 (10mol), or the pCCL28-IZ-gD (1mol) construct, can
establish an efficient immune defense against a lethal dose of HSV-2 challenge by
various mechanisms, including by activating relevant immune cells, to reduce the
morbidity and mortality. The immunized mice were challenged i.vag. with a lethal
dose of HSV-2 at 9 weeks postboost. Following challenge, the weights and clinical
symptoms of the mice were monitored daily up to 15 dpi. The blood, vaginal lavage
fluid, and sacral ganglia were sampled at the indicated time points, and thereafter
we investigated viral shedding and latent viral DNA loads postchallenge.
(i) Weight change. After HSV-2 challenge, mice immunized with pcDNA3.1 exhib-
ited apparent weight loss at 1 dpi, followed by a sharper loss after 6 dpi. In contrast, no
apparent weight loss was observed when mice were coimmunized with pgD plus
pCCL19, pCCL28, or pCCL28-IZ-gD. In fact, a significant weight increase compared with
pgD plus pcDNA3.1 was observed (Fig. 6A).
(ii) Disease severity. For all of the less effective groups, symptoms began to appear
at 2 dpi. In line with previous findings of mice immunized with pcDNA3.1, they devel-
oped severe symptoms rapidly, and all were dead at 13 dpi (28). In contrast, almost
40% of mice immunized with pgD plus pcDNA3.1 also developed relatively mild symp-
toms 3 dpi (inflammation, genital ulceration, and hair loss). Meanwhile, unlike the
FIG 6 Protective efficacies of vaccine formulations during lethal vaginal HSV-2 challenge. Nine weeks postboost, mice were challenged i.vag. with a lethal
dose of HSV-2. Vaccinated and control groups were monitored for up to 15 days for weight changes, illness features, and mortality. The figure shows
weight changes (A), disease severity (B), viral shedding in vaginal lavage fluid (C), and latent viral DNA loads (D). Viral shedding was detected by plaque
assay at the indicated time points. The dashed line indicates the detection limit. Latent viral DNA in the sacral ganglia was quantified by real-time PCR at
30 dpi or the date of death. The values 6  ND, 8  ND, and 9  ND indicate the number of mice without latent virus. Data shown are the means 6 SEM
for each group (n= 5 or 7 mice/group) from at least two independent experiments with each condition performed in duplicate. Statistically significant
differences determined by comparing to the pgD 1 pcDNA3.1 group are indicated. NS, not statistically significant; ***, P, 0.001. ND, no virus detected.
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other groups, mice coimmunized with pgD plus pCCL19, pCCL28, or the pCCL28-IZ-gD
construct did not show apparent symptoms (Fig. 6B).
(iii) Viral shedding. Viral loads in vaginal lavage fluid were detectable but dropped
sharply in all groups; however, viral loads were the highest in the negative-control
group and moderately high in the pgD plus pcDNA3.1 group, and the symptoms in
the genital tracts and nerves of the negative-control mice were too severe to sample
at 6 dpi. All of the mice were dead at 13 dpi. In contrast, viral shedding at mucosal sites
was sharply decreased in the pgD plus pCCL19 or pCCL28 and pCCL28-IZ-gD groups.
Those mice all survived, and their viral loads in the vaginal lavage fluid dropped below
the detection limit at 7 dpi. Of note, viral reshedding was observed at 15 dpi in the
pgD plus pcDNA3.1 group (Fig. 6C). Similar viral shedding incidences were observed in
mice postchallenge (Table 1).
(iv) Latent viral DNA. As described previously (28), the latent HSV-2 genomes in
murine sacral ganglia were quantified at 30 dpi or at the time of death. The immuniza-
tion groups ranked from highest to lowest number of latent HSV-2 genome copies
were pcDNA3.1, pgD plus pcDNA3.1, pgD plus pCCL19, pgD plus pCCL28, and pCCL28-
IZ-gD. There were no significant differences between the last three groups, indicating
that both CCL28- and CCL19-enhanced Ag-specific responses could prevent HSV-2
from establishing latent infection after lethal challenge (Fig. 6D).
Overall, we initially tested the dose effects of CCL19 and CCL28 to help enhance
HSV-2 gD immunogenicity and protect against lethal doses of viral challenge. The
results showed that the doses of 20mol pCCL19 and 10mol pCCL28, and an even
lower dose of a 1:1 ratio of Ag and CCL28 constructs, can protect mice against HSV-2
challenge without weight loss or any apparent symptoms (Table S3). In summary, a
high dose of CCL19 is helpful in inducing protective immunity, especially humoral im-
munity; however, the low dose of CCL28 demonstrated a more potent enhancement
of cellular responses in the protective immune response.
DISCUSSION
A prophylactic HSV-2 vaccine should induce powerful humoral, cellular, and muco-
sal immunity, which should sterilize HSV-2 shedding and reduce recurrent lesions in
the long term (37). Based on our previous study evaluating general chemokines in
combination with HIV-1 Env (8), our results show that both CCL19 and CCL28 can aug-
ment systemic and mucosal immune responses, while CCL19 can enhance HSV-2 gB-
induced protective mucosal immune responses (28). In this study, we systematically
compared CCL19 and CCL28 as molecular adjuvants in combination with the vaccine
candidate HSV-2 gD to assess whether they promote protective immunity in mice.
It has been reported that mucosa-associated adjuvants codelivered with immuno-
gens can enhance protective immune responses (15, 38, 39). In our study, we found
that CCL19 and CCL28 showed dose-dependent differences in their protection against
challenge (Fig. S2). Our results also suggest that an effective combination vaccine
needs less CCL28 than CCL19. In addition, as for a preventive vaccine against mucosally




No. (%) of mice challenged with HSV-2 and virus shedding
incidences by day dpi
1 3 5 7 9 11 15
pcDNA3.1 14 14 (100.0) 14 (100.0) 14 (100.0) — — — —
pgD1 pcDNA3.1 13 13 (100.0) 13 (100.0) 10 (76.9) 7 (53.8) ND ND 2 (15.4)
pgD1 pCCL19 13 13 (100.0) 8 (61.5) 3 (23.1) ND ND ND ND
pgD1 pCCL28 12 12 (100.0) 7 (58.3) 4 (33.3) ND ND ND ND
PCCL28-IZ-gD 10 10 (100.0) 9 (90.0) 5 (50.0) ND ND ND ND
aHSV-2 shedding incidences in vaginal liquids were detected by real-time PCR. Data shown are from 3 or 4
independent experiments. HSV-2 shedding incidence = (number of vaginal liquids from which viral DNA was
detected/total number of vaginal liquids analyzed) 100.—, not obtainable for serious disease. ND, no virus
was detected.
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transmitted viruses such as HSV-2, a strong and rapid mucosal antibody response is
required, which can be achieved by a good memory B cell response (40, 41).
Compared with CCL19, here we found that CCL28 has an advantage in inducing long-
lasting serum neutralizing Abs postchallenge and more potent systemic Abs, which
may be the dominant reason for the rapid removal of HSV-2 after challenge and the
reduction in establishing latent infection. At the same time, we found that the pgD
plus pCCL19 group produced less serum inflammatory cytokines postchallenge, sug-
gesting that the instant recalled neutralizing Abs are more important for viral clearance
in the early period of challenge. Previous studies found that CCL19 and HSV-1 gB (15)
used in combination could enhance HSV-1 gB-specific systemic IgG and IgA in sera
during the memory response. In agreement, our results further demonstrated that
CCL19 or CCL28 used in combination with gD or as a fusion construct could signifi-
cantly enhance the levels of humoral and mucosal protective Abs as well as the dura-
tion of protective immune responses compared with gD alone.
However, it has also been concluded from several animal studies that robust hu-
moral immunity alone is ineffective in the control of HSV-2 infection (29, 30). An ideal
prophylactic vaccine should not only produce a potent humoral immune response but
also promote T cell immune responses (15, 32). To this end, we demonstrated that
both CCL19 and CCL28 as adjuvants could promote enhanced gD-specific Th1- and
Th2-like cellular responses postimmunization. Previous studies demonstrated that gD-
specific IgG2a contributed to a potent neutralizing capacity against HSV-2 in guinea
pigs (32). Consistent with some studies (29, 30), our results indicated that HSV-2 gD
induces a relatively reduced IgG2a profile, while CCL19 or CCL28 in combination with
gD or as a chimeric construct can preferentially induce the IgG2a subtype after immu-
nization and viral challenge; however, codelivery with less CCL28 was more potent
than CCL19 in inducing Th1-like IgG2a responses, cytokine-associated Th1/Th2-associ-
ated responses, and murine T cell migration to secondary lymph tissues postboost and
postchallenge. However, although the pCCL28-IZ-gD chimeric construct produced a
Th1-like IgG2a response similar to that by pgD with 20mol pCCL19, it produced a sig-
nificantly higher Th1-associated IFN-g response and higher virus-responsive CCR101 T
cell, B cell, and DC immigration rates postchallenge. Taken together, these results indi-
cate that CCL28 is more potent than CCL19 in promoting a higher magnitude and lon-
ger duration of Ag-responsive Th1- and Th2-like cellular immunity during viral chal-
lenge, implying that a stronger cellular immunity also is important in achieving
mucosal immune protection against genital herpes.
Likewise, it is necessary to prove that an appropriate immune response is induced
in the mucosal sites to protect against sexually transmitted pathogens. In this study,
we developed a DNA construction platform that allows bicistronic and chimeric
expression of an Ag and chemokine using IRES and IZ linkers, respectively. In the cur-
rent study, some linkers may favor enhanced immune responses by facilitating expres-
sion of the Ag and adjuvant in the same cell and tissue (27, 28). In addition, as a proof-
of-concept study, we adopted a platform for expressing gD and chemokine at a 1:1
ratio to further reveal the working program and efficiency of chemokines in vivo,
although their optimal doses for triggering appropriate immune responses warrant fur-
ther investigation. Nevertheless, the CCL28 IZ-based chimeric construct has shown effi-
cacy in priming a robust immune response, particularly a cellular response. Here, the IZ
linker demonstrated an advantage over IRES in inducing potent immune responses
and protecting mice against viral challenge. We also showed that CCL28 as an adjuvant
has a relatively high efficiency in promoting HSV-2 gD-responsive immune protection.
Compared to our previous study (28), molecular adjuvant CCL19 combined with HSV-2
gB and IZ linker can produce potent immunity during immune protection rather than
CCL28 (data not shown), indicating that required adjuvants vary with different Ags
rather than depending on the roles of adjuvants.
In conclusion, our results demonstrate that CCL19 and CCL28 can promote durable,
Ag-specific, systematic, and mucosal antibody responses as well as enhanced Th1- and
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Th2-like cellular responses postimmunization and postchallenge. These enhanced
recall responses postchallenge contribute to protecting mice against a lethal dose of
HSV-2 challenge. Although future work is warranted to assess the effects of our vaccine
candidates in other animal models, findings in this study provide a theoretical basis for
vaccine development to exert similar efficacy in humans. Since HSV-2 transmission
mostly occurs in localized mucosal sites, the genital herpes model enables us to dissect
the roles of different chemokines in recalling mucosa-associated immune responses.
Our study suggests that the immune potentiation of these chemokine-formulated vac-
cines is applicable in pharmaceutical strategies for prophylaxis and in managing
human genital herpes.
MATERIALS ANDMETHODS
DNA constructs. Murine CCL19 and CCL28 chemokine constructs were described previously (8),
namely, plasmids pCCL19 and pCCL28. The Ag-truncated gD ectodomain (gD-306aa) was amplified from
the HSV-2 G strain genome (LGC Standards) as described previously (42, 43). Constructs of chemokine-
Ag (chemokine-IRES-gD, gD-IRES-chemokine, chemokine-IZ-gD, and gD-IZ-chemokine) containing the
internal ribosome entry site (IRES) of the encephalomyocarditis virus (EMCV) or IZ linker [(Gly4Ser)2-IZ-
(Gly4Ser)2] were designed and cloned into pIRES2 (Clontech, USA) or pcDNA3.1(1) (Invitrogen, USA) by
following the methods described previously (8). Truncated gD was also cloned into the prokaryotic
expression plasmid pET28a (Novagen, USA), termed pET-gD. For the IRES-based chemokine-Ag DNA vac-
cines, both chemokine and the Ag coding gene were accompanied by a stop codon to encode the bicis-
tronic expression constructs. For IZ-based chemokine-Ag DNA vaccines, coding genes placed after the IZ
linker had no signal peptides, and a single stop codon was placed at the 39 end of the IZ[(Gly4Ser)2-IZ-
(Gly4Ser)2]-linked fusion constructs. For both IRES and IZ designs, we generated constructs with both Ag
and chemokines before and after the IRES and IZ sequences, respectively (Fig. 1A; see also Fig. S1A in
the supplemental material). Appropriate restriction sites were introduced into the chemokine and Ag
coding genes, and they were amplified by splicing overlap extension PCR (27). The PCR primers used in
plasmid construction are listed in Tables S1 and S2. The constructs were extracted using the Pro Filter
Plasmid Midi/Maxi extraction kit (Macherey-Nagel, Germany) and confirmed by sequencing.
Cell lines and HSV-2 titer. Vero and HEK 293T cell lines (ATCC CRL-1573) were cultured in complete
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, USA) supplemented with 10% fetal bovine se-
rum (FBS) (Invitrogen, the Netherlands), 100 U/ml penicillin, and 100mg/ml streptomycin (Invitrogen,
USA).
As described previously (44), the HSV-2 G strain (2.4 106 PFU/ml) was propagated on a Vero cell
monolayer (multiplicity of infection of 5). At 36 to 48 h, supernatant virus and cell-associated virus
(freeze-thawed three times) were harvested and filtered (0.45mm). Viral stocks were aliquoted and
stored at280°C. The number of PFU of HSV-2 was determined by a plaque assay before use.
Prokaryotic gD protein expression and purification. gD protein was produced in Escherichia coli
as described previously (28), with modifications. In brief, the E. coli Rosetta strain (Novagen, USA) was
first transformed with pET-gD and then induced with isopropyl-b-D-thiogalactoside (IPTG) for 4 h for gD
production. Afterwards, the gD protein produced in the bacteria as insoluble inclusion bodies was
released by ultrasonic treatment and collected by centrifugation (30min, 1,200 g at 4°C). The insoluble
protein in the lysates was washed twice with phosphate-buffered saline (PBS) plus 1 M guanidine hydro-
chloride (GuHCl) and subsequently resuspended with denaturing buffer (10mM Tris, 500mM NaCl, 6 M
GuHCl, and 5mM dithiothreitol, pH 8.0) over 12 h, followed by refolding in refolding buffer (20mM Tris-
Cl, 500mM NaCl, 3mM glutathione, 0.3mM glutathione disulfide, 10% glycerol, pH 8.0) for 48 h at 4°C
(45). Refolded gD protein was purified by nickel-charged Sepharose (GE Healthcare, USA) according to
the manufacturer’s instructions. A six-His tag on the C terminus of gD facilitated its purification, followed
by elution with imidazole buffer (20mM Tris-Cl, 500mM NaCl, 3mM glutathione, 0.3mM glutathione di-
sulfide, 300mM imidazole, 10% glycerol [pH 8]). Subsequently, purified gD protein was dialyzed and ali-
quoted, and the concentration was determined with a bicinchoninic acid assay kit (Thermo Scientific,
USA) before use. The quality of the purified gD protein was also determined by SDS-PAGE and Western
blotting (28). Purified products were stored at 280°C.
Mice, immunizations, and sampling. Naïve female BALB/c mice (Beijing HFK Biotechnology) aged
6 to 8 weeks were used for plasmid immunization and housed under specific-pathogen-free (SPF) condi-
tions. All experimental procedures involving animals were performed in accordance with the terms
approved by the Institutional Animal Care and Use Committee and the Hubei Laboratory Animal Science
Association (approval no. WIVA11201301). The prime and boost immunization strategy is shown in
Fig. 1B, and the immunization procedure was carried out as described previously (17, 28). In brief, each
randomly grouped mouse (n= 10 per group) was injected intramuscularly (i.m.) with various doses of
plasmids in a volume of 40ml into the quadriceps muscles, which was followed by three pulses of elec-
troporation (100 V, 50ms) and another three pulses with reversed electrode polarity. As shown in
Table S3 in the supplemental material, mice were coimmunized with 1mol gD-encoding plasmid (pgD)
plus 1, 10, or 20mol pCCL19/pCCL28 monovalent DNA plasmid or immunized with 1mol chimeric DNA
construct per mouse (i.e., pCCL19/CCL28-IRES-gD, pgD-IRES-CCL19/CCL28, pCCL19/CCL28-IZ-gD, or
pgD-IZ-CCL19/CCL28). For the negative-control group, mice were immunized with an equivalent
amount of control vector (pcDNA3.1). As described previously (17), animals were immunized twice at 2-
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week intervals. Serum and vaginal lavage samples were collected at 2 and 7 weeks postboost. Vaginal la-
vage samples were collected by washing the vagina three times with PBS containing protease inhibitors
(Roche, China). Samples were aliquoted and stored at 280°C until use.
HSV-2 challenge, scoring, and virus shedding. Five days prior to HSV-2 challenge, each mouse
was injected subcutaneously (s.c.) with medroxyprogesterone acetate (2mg). At 7 weeks postboost,
mice (n= 5) were challenged intravaginally (i.vag.) with 10ml per mouse of HSV-2 (2.4 107 PFU/ml) af-
ter pentobarbital anesthetization. Weight loss was monitored daily, and the manifestations of vaginal
inflammation were scored according to criteria reported by Skoberne et al. (32) and specified from 0 to
5 (0, no apparent inflammation; 1, mild inflammation; 2, redness and moderate swelling; 3, severe red-
ness and inflammation; 4, genital ulceration and severe inflammation; 5, hind-limb paralysis and death).
Serum and vaginal lavage samples were collected at the indicated day postinfection (dpi) (Fig. 1B) and
used for the detection of Ag-specific IgG titers, viral neutralization Ab titers, Ag-specific inflammatory
cytokine responses, and viral shedding. Viral shedding in vaginal lavage samples was tested by plaque-
forming assay on Vero cell monolayers as described previously (32, 46). Sacral ganglia were collected at
30 dpi or at the time of mouse death, and then the latent viral load in the ganglia was detected with
DNA quantitative fluorescent PCR. HSV-2 DNA extraction and testing were carried out according to a
previous study (47). All samples were tested in triplicate.
Expression analyses of gD and chemokines. HEK 293T cells were transfected with 0.5mol
pcDNA3.1, pgD plus pcDNA3.1, pgD plus pCCL19, pgD plus pCCL28, and chimeric construct pCCL28-IZ-
gD, respectively, for 48 h, and supernatants were harvested and analyzed by 12% denaturing SDS-PAGE
and 4 to 15% continuous gradient native PAGE, respectively. The gD glycoprotein moiety in the
recombinant proteins was detected by Western blotting, as previously described (28). Anti-gD monoclo-
nal antibody (MAb) (0191; Santa Cruz Biotechnology, USA) and horseradish peroxidase (HRP)-labeled
donkey anti-sheep IgG (Santa Cruz Biotechnology, USA) were used to detect gD expression. Chemokines
were detected using the CCL19 and CCL28 DuoSet ELISA kit (R&D Systems, USA), respectively.
Tissue processing and harvesting. At 2 weeks postboost, spleens and mesenteric lymph nodes
(MLNs) were removed under sterile conditions, and a single-cell suspension was obtained by pressing
samples through a 70-mm Falcon cell strainer (BD Biosciences, China). Mouse immunocytes were iso-
lated using mouse 1 lymphocyte separation medium according to the manufacturer’s instructions
(Dakewe Biotech, China). Finally, red blood cells were lysed by red blood cell lysis buffer (Sigma-Aldrich,
USA). Purified immunocytes were resuspended in complete RPMI 1640 medium and counted using an
automated cell counter (Bio-Rad, USA).
Virus neutralization assay. The neutralization activities of sera and vaginal lavage fluid were tested
using plaque assays as described previously, with modifications (2). Briefly, heat-inactivated sera (56°C
for 1 h) were prepared in 2-fold serial dilutions from 1:10 to 1:1,280 (postboost) or from 1:40 to 1:5,120
(postchallenge) in DMEM (without FBS). Vaginal lavage fluid was prepared in 2-fold serial dilutions from
1:5 to 1:40 (postboost) in DMEM (without FBS). The diluted samples (in triplicate) were subsequently
incubated with 100 PFU/ml of HSV-2 for 1 h at 37°C. Following incubation, the sample-virus mixture was
added to Vero cells in 48-well culture plates (preseeded at 1.2 105 cells per well 1 day before the
assay). Cells receiving HSV-2 alone were included as positive controls, whereas cells without the sample-
virus mixture were used as background controls. Sera from pcDNA3.1 immunized mice at the same dilu-
tion were considered controls for nonspecific background in inhibiting plaque formation. After incuba-
tion for 48 h, cells were stained with crystal violet and the plaques were counted for HSV-2 titration. The
Ab-mediated neutralization activity was determined based on the dilution titer that reduced the number
of plaques by 50% compared with the positive control and was expressed as the log10 of the dilution
titer.
Ag-specific IgG, IgA, and IgG subclasses. gD-specific IgG and IgA endpoint titers in sera and vagi-
nal lavage fluid were measured by indirect ELISA, as described in our previous study (47). In brief, 96-
well microplates (Nunc Maxisorp; Thermo Scientific, USA) were coated with purified gD (2mg/ml, 50ml/
well) overnight at 4°C and then washed 5 times with wash buffer and blocked with blocking buffer.
Thereafter, plates were incubated with serially diluted samples at 37°C for 1 h. Plates were washed 5
times again and incubated with HRP-conjugated goat anti-mouse IgG (Abcam, USA) or biotin-conju-
gated goat anti-mouse IgA (Southern Biotechnology, USA) at a dilution of 1:5,000 at 37°C for 1 h. For IgA
detection, plates were washed 5 times and incubated with streptavidin-HRP (R&D Systems, USA) at a
dilution of 1:200 at 37°C for 0.5 h. After 5 washes, bound HRP conjugates were detected by a TMB-based
colorimetric reaction at room temperature for 5min. This reaction was stopped with 2 N H2SO4. The
color intensity was read by an automated ELISA reader (Tecan, Switzerland). Endpoint titers were calcu-
lated using GraphPad Prism 8.0. Sample dilutions with an optical density at 450 nm (OD450) higher than
the OD450 of the negative control plus 2 standard deviations (SD) at the same dilution were considered
positive.
The titers of gD-specific isotype subclass Abs in immunized and virus-challenged murine sera were
measured by HRP-conjugated anti-mouse IgG1, IgG2a, IgG2b, IgG3, and IgM (Southern Biotechnology,
USA) according to the manufacturer’s instructions. Antibody concentrations were calculated based on
standard curves.
Ag-specific inflammatory cytokine responses. Postchallenge splenocytes (1 107/well) were
added to duplicate wells in 24-well plates in a total volume of 1ml complete RPMI 1640 with purified gD
protein (2mg/ml) as a stimulus and cultured at 37°C for 5 days. After incubation, cell culture superna-
tants were filtered and used for the detection of Th1/Th2 cytokines (IL-2, IL-4, IL-5, IFN-g, and TNF-a). In
addition, antisera were collected at 5 and 9 dpi and used for the detection of Th1/Th2 cytokines. The
analysis was performed with a BD cytometric bead array mouse Th1/Th2 cytokine kit (BD Biosciences,
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China) according to the manufacturer’s instructions. Data acquisition was conducted on a BD FACSAria
III platform and analyzed by FCAP Array software 2.0.
Immunohistochemistry of rectal mucosae. At 2 weeks postboost, murine colorectal samples were
collected and analyzed for IgA1 cell number by immunohistochemistry in accordance with the proce-
dures described previously, with some modifications (8, 20). In brief, an approximately 2-cm segment
from the end of the anus of each mouse was isolated, cut open longitudinally, and fixed in neutral buf-
fered formalin (diluted 1:10 in PBS) for 24 h. After fixation, tissue was embedded and sectioned. Ag re-
trieval was performed with the Ag retrieval reagent-basic (R&D Systems, USA) according to the manufac-
turer’s instructions. For the detection of IgA1 cells, the slides were first stained with goat anti-mouse IgA
antibody (AbD Serotec, UK) at a dilution of 1:400 overnight at 4°C, followed by incubation with the
Polink-2 plus polymer HRP detection system for goat primary antibody (GBI, China) according to the
manufacturer’s instructions. A color reaction was developed with the addition of 3,39-diaminobenzidine
free base (DBA), followed by counterstaining with hematoxylin.
Chemokine-specific chemotaxis reactions. Chemotaxis assays with purified splenocytes and MLN
lymphocytes (MLNLs) were performed as previously described (28). A microchamber Transwell system
with 3-mm pores (Corning Costar, USA) was used in the chemotaxis assays. In brief, 2 106 cells/well (in
300ml complete RPMI 1640 medium) were plated in triplicate in the upper chambers, and 600ml com-
plete RPMI 1640 medium with or without (negative control) 30 ng/ml CCL19 or 500 ng/ml CCL28 (R&D
Systems, USA) was added into the lower chambers. The plates were incubated at 37°C for 90min, and
the number of migrated cells was counted using a Bio-Rad automated cell counter. The fold change in
migration was calculated as migrated cell number in testing wells divided by migrated cell number in
negative-control wells.
Statistical analysis. Comparisons between two groups were done using the nonparametric t test,
while more than three groups were analyzed by two-way analysis of variance with Dunnett’s correction
analysis (GraphPad Prism 8.0). Data are presented as the means 6 standard errors of the means (SEM). A
P value of,0.05 was considered statistically significant.
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